Aridis Pharmaceuticals, Inc. ARDS

I have 8000 shares@3.73????

Aridis Pharmaceuticals Inc. (NASDAQ: ARDS)

Another decent gainer of the day is Aridis Pharmaceuticals Inc., which climbed by over 6% at EOD on December 22nd. It’s worth noting that we’ve covered ARDS stock plenty of times in the past few weeks for its sizable rises. This includes a five-day gain of more than 35% despite a YTD drop of around 50%. While its yearly performance is nothing to write home about, many investors are watching ARDS stock right now for its recent bullish turnaround.

The major reason for its gains comes as the biotech penny stock reported positive news surrounding its monoclonal antibody cocktail’s protection against the Omicron variant. Specifically, the treatment known as AR-701, binds to different proteins in the Covid virus, which allows for refusal of entry into the host’s cells. The company also states that the compound could provide high levels of drug concentration for up to one year from the time of treatment.

“Omicron has rendered current COVID-19 vaccines and monoclonal antibodies substantially less effective, and likely future COVID 19 variants will arise that continue this trend. Our laboratory data suggest that AR-701 has the potential to be a future-proof COVID-19 therapy that can protect against SARS-CoV-2, SARS, or MERS pandemics.”

The CEO of Aridis Pharmaceuticals, Vu Truong
This is big news, especially considering the major rise in cases in the past few weeks. So whether this makes ARDS stock worth buying or not is up to you.

? long term holding?

Aridis Pharmaceuticals Inc. (NASDAQ: ARDS)

Another decent gainer of the day is Aridis Pharmaceuticals Inc., which climbed by over 6% at EOD on December 22nd. It’s worth noting that we’ve covered ARDS stock plenty of times in the past few weeks for its sizable rises. This includes a five-day gain of more than 35% despite a YTD drop of around 50%. While its yearly performance is nothing to write home about, many investors are watching ARDS stock right now for its recent bullish turnaround.

The major reason for its gains comes as the biotech penny stock reported positive news surrounding its monoclonal antibody cocktail’s protection against the Omicron variant. Specifically, the treatment known as AR-701, binds to different proteins in the Covid virus, which allows for refusal of entry into the host’s cells. The company also states that the compound could provide high levels of drug concentration for up to one year from the time of treatment.

“Omicron has rendered current COVID-19 vaccines and monoclonal antibodies substantially less effective, and likely future COVID 19 variants will arise that continue this trend. Our laboratory data suggest that AR-701 has the potential to be a future-proof COVID-19 therapy that can protect against SARS-CoV-2, SARS, or MERS pandemics.”

The CEO of Aridis Pharmaceuticals, Vu Truong
This is big news, especially considering the major rise in cases in the past few weeks. So whether this makes ARDS stock worth buying or not is up to you.

Gogogo up??????

I have 6000 shares @4.1????
What should I say?
Better don’t move now. Time will win.

Will shot soon???????

I would not worry too much!6000shares @4.1??

Set up to buy 5000 shares when opening ???

$OBSV
Don’t mis this run. Lots of upside potential.

ObsEva SA (NASDAQ:OBSV) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Shareholders will be ecstatic, with their stake up 30% over the past week following ObsEva SA‘s (NASDAQ:OBSV) latest quarterly results. Revenues came in 113% better than analyst models expected, at US$4.0kwhile statutory losses per share were US$0.48, in line with forecasts. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.